Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Maintaining Viral Suppression in HIV: Insights on Switching Treatments and Emerging Agents : Episode 1
HIV Viral Suppression: Clinical Significance and Impact on Patient Outcomes
A panelist discusses how viral suppression in HIV patients means achieving undetectable virus levels (below 50 or 20 copies per ml), which prevents immune system damage and transmission to others, summarized as "undetectable equals untransmissible" (U=U).
Now Viewing
EP: 1.HIV Viral Suppression: Clinical Significance and Impact on Patient Outcomes
EP: 2.Changing Patient Demographics in HIV and Impacts of Polypharmacy on Treatment
EP: 3.Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials
EP: 4.HIV Therapy Without Integrase Inhibitor: Practical Advantages and Targeted Patient Populations
EP: 5.Long-Acting HIV Therapies: Real-World Data and Clinical Application
EP: 6.CD4 T-cell and Lymphocyte Monitoring: Clinical Significance in HIV Treatment
EP: 7.CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments
Viral Suppression in HIV Management
Key Themes:
- Definition of Viral Suppression
- Viral suppression means HIV viral load is below detectable levels on laboratory tests
- Current laboratory standards define suppression as less than 50 copies/ml or less than 20 copies/ml
- Clinical Significance
- Suppression indicates virus is not replicating, preventing further immune system damage
- Regular viral load monitoring is essential for confirming ongoing suppression
- Transmission Prevention
- Dr. Walmsley highlighted the "U=U" principle: "Undetectable equals Untransmissible"
Virally suppressed patients cannot transmit HIV to others, representing a major advancement
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
